hVIVO (LON:HVO) Announces Earnings Results

hVIVO (LON:HVO) posted its quarterly earnings results on Tuesday. The company reported GBX (0.82) EPS for the quarter, Digital Look Earnings reports. hVIVO had a negative return on equity of 14.65% and a negative net margin of 12.48%.

hVIVO Trading Down 5.2%

Shares of HVO stock traded down GBX 0.34 on Tuesday, hitting GBX 6.07. 3,615,038 shares of the company’s stock traded hands, compared to its average volume of 2,547,161. The stock has a market capitalization of £41.75 million, a price-to-earnings ratio of -6.97 and a beta of 1.69. The company’s fifty day simple moving average is GBX 6.83 and its 200 day simple moving average is GBX 7.42. hVIVO has a one year low of GBX 4.30 and a one year high of GBX 11. The company has a debt-to-equity ratio of 38.75, a quick ratio of 1.16 and a current ratio of 1.63.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.